Oct. 19, 2022
The College's COVID-19 NewsBrief provides timely curated COVID information and helpful resources for use in your practice and with your patients.

PHE extended for 90 days

HHS has extended the COVID-19 Public Health Emergency through Jan. 11, 2023. Renewal of the PHE allows for policies to remain in place, such as emergency authorizations of drugs, health care coverage through Medicare/Medicaid, and more. A notice of 60 days will be provided when it is decided to terminate the PHE. The Biden Administration has signaled HHS is preparing to end the PHE in the near future. In separate communications, they urged states and providers to prepare for an end to the PHE.

Bivalent vaccines approved for younger children

The CDC approved bivalent vaccines for children ages 5 to 11. The decision follows the FDA’s authorization of updated COVID-19 vaccines from Pfizer-BioNTech for children ages 5 through 11 years, and from Moderna for children and adolescents ages 6 through 17 years.

Infections from BQ.1 and BQ.1.1 cases rising

COVID Omicron variants BQ.1 and BQ.1.1 make up an estimated 10% of new cases across the United States. Omicron variant BA.5 remains the dominant strain of the virus. The BQ.1 and BQ.1.1 variants appear to be on track to overtake variant BA.4.6, which currently makes up about 12% of infections.

Visit the College's COVID-19 page

The College’s COVID-19 resource page has information related to COVID that allergists may need. 
Copyright © 2022 American College of Allergy, Asthma and Immunology, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list